SCHEMBL8286290

SCHEMBL8286290

Cc1cc([N+](=O)[O-])c(Cl)s1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.41
GPR35 Q9HC97 4/20 0.41
CYP3A4 P08684 3/20 0.41
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 3/20 0.39
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
HIF1A Q16665 1/20 0.37
TXNRD1 Q16881 1/20 0.37
TXNRD3 Q86VQ6 1/20 0.37
TXNRD2 Q9NNW7 1/20 0.37
CYP1A2 P05177 1/20 0.37
VCAM1 P19320 1/20 0.37
RECQL P46063 1/20 0.37
GAA P10253 1/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660245 0.78 TSHR (0.44) TSHRGPR35CYP3A4MAPK1TDP1
SCHEMBL5196770 0.78 PSMB8 (0.46) TSHRGPR35CYP3A4TDP1HSD17B10
SCHEMBL4665919 0.77 MEN1 (0.44) TSHRGPR35CYP3A4MAPK1TDP1
SCHEMBL18357928 0.75 CYP3A4 (0.46) TSHRGPR35CYP3A4MAPK1TDP1
SCHEMBL29965062 0.75 CYP1A2 (0.46) TSHRGPR35CYP3A4TDP1HSD17B10
SCHEMBL14441148 0.75 USP7 (0.41) TSHRGPR35CYP3A4MAPK1TDP1
SCHEMBL2681454 0.73 USP7 (0.58) GPR35CYP3A4CYP1A2VCAM1
SCHEMBL2681533 0.72 VCAM1 (0.44) TSHRGPR35CYP3A4MAPK1TDP1
SCHEMBL12104562 0.71 TSHR (0.46) TSHRGPR35TDP1
SCHEMBL1456043 0.71 DAO (0.55) TSHRGPR35VCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1684745-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-12-17 EP disclosed
EP-2033654-B1 Process for resolving a mixture of alkyl ester enantiomers using an enzyme BRISTOL MYERS SQUIBB CO (US) 2012-05-16 EP disclosed
EP-2033654-A1 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus Bristol-Myers Squibb Company (US) 2009-03-11 EP disclosed
EP-1629000-B1 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2009-02-18 EP disclosed
US-7309708-B2 Hepatitis C virus inhibitors BIRSTOL-MYERS SQUIBB COMPANY (US) 2007-12-18 US disclosed
US-7309708-B2 Hepatitis C virus inhibitors BIRSTOL-MYERS SQUIBB COMPANY (US) 2007-12-18 US disclosed
US-7173004-B2 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed
US-7173004-B2 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed
US-7173132-B2 Certain substituted 1-aryl-3-piperazine-1′-yl propanones MOLECULAR GERIATRICS CORPORATION (US) 2007-02-06 US disclosed
WO-2005054430-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-16 WO disclosed
WO-2004094452-A2 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 WO disclosed
WO-2003099316-A1 HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed